DSGN

Design Therapeutics, Inc.
CAPPED RATING

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics, Inc. (DSGN) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.5 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.8
EV / EBITDA -5.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -27.4%
Price Return 12M 40.9%
Catalyst Signal 0.00
Market Cap $682.0M
TTM Revenue N/A
Price / Sales N/A
ROE -36.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) D+ (1.5) D+ (1.7) C (2.2) C+ (2.6) C- (2.1)
2026-11-04 C+ (2.5) D (1.4) D+ (1.7) C+ (2.7) C+ (2.7) C (2.2)
2026-10-28 C+ (2.5) D (1.4) D+ (1.7) C+ (2.8) C+ (2.7) C (2.2)
2026-10-21 C+ (2.5) D (1.4) D+ (1.7) C+ (2.8) C+ (2.6) C (2.2)
2026-10-14 C+ (2.5) D (1.4) D+ (1.7) C+ (2.7) C+ (2.6) C (2.2)
Page 1 of 4